Global SARS-CoV-2 Expert Symposium 2022

SARS-CoV-2 Experts Panel Discussion Session 2

Chaired by Dr. Jeremy Fry, ProImmune

Panel: Prof. Stephen Kent, Prof. Marcus Buggert, Prof. Paul Klenerman, Dr. Nawamin Pinpathomrat

Prof. Paul Klenerman

Oxford University, UK

“PITCH: Covid-19 immunity studies in a UK Health Care Worker Cohort”

Prof. Marcus Buggert

Karolinska Institute, Sweden

“SARS-CoV-2-specific T cell responses in healthy and immunodeficient patients”

Dr. Nawamin Pinpathomrat

Prince of Songkla University, Thailand

“Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in healthy general population”

Edmund Neo

ProImmune, Singapore

“Epitope identification and clinical immune monitoring tools ”

SARS-CoV-2 Experts Panel Discussion Session 1

Chaired by Prof. Antonio Bertoletti, Duke-NUS

Panel: Prof. William Liu Jun, Prof. Nikolai Petrovsky, Dr. Jennifer Juno

Prof. Nikolai Petrovsky

Vaxine, Australia

“Covax19/Spikogen®; the first approved recombinant spike protein vaccine”

Dr. Leo Swadling

University College London

“Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection”

Prof. William Liu Jun

Chinese National Influenza Center

“Seeing the antiviral T cell immunity: believing the epitope based vaccines”

Dr. Jennifer Juno

University of Melbourne

“Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory”

ProImmune SARS-CoV-2 Expert Symposium 2021

Dr. Yanchun Peng

University of Oxford

“The role of antigen-specific T cell responses in SARS-CoV-2 infection”

SARS-CoV-2 Expert Panel Discussion 1

Eui-Cheol Shin, Nina Le Bert, Tao Dong, Yanchung Peng

“Topics include what has been most surprising about SARS-Cov-2, importance of T cell immunity and insights into reinfection”

SARS-CoV-2 Expert Panel Discussion 2

Alex Sette, Antonio Bertoletti, Kate Broderick

Topics include booster vaccine effectiveness, modified vaccines for different VoCs and the future of the pandemic

Dr. Kate Broderick

Inovio Pharmaceuticals Inc.

“INO-4800 – A DNA based vaccine against COVID-19”

Prof. Alessandro Sette

University of California, La Jolla Institute for Immunology

“Study of adaptive responses to SARS CoV2”

Edmund Neo


“Epitope identification and clinical immune monitoring tools”

Prof. Eui-Cheol Shin

Korea Advanced Institute of Science and Technology (KAIST)

“Phenotypes and functions of SARS-CoV-2-specific T cells”

Dr. Nina Le Bert

Duke-NUS Medical School

“SARS-CoV-2-specific T cells in infection and vaccination: a case for their protective role”

Prof. Katie Ewer

University of Oxford

“T cell responses to the Oxford / AZ COVID-19 vaccine in UK clinical trials”

Mastering Immunity Europe 2021

Dr. Geoff Hale


“Characterisation of novel antibodies which are completely silenced with respect to Fc”

Dr. Jeremy Fry


“An integrated approach to managing immunogenicity risk and drug immune modulation”

Dr. Derek Doherty

Trinity College Dublin

“CD1d-restricted T cells in patients with oesophageal cancer”

Dr. Quirin Hammer

Karolinska Institute

“HLA-E-restricted peptides control natural killer cell responses”

Edmund Neo


“Clinical Immune Monitoring in Gene Therapy, Immuno-Oncology and SARS-CoV-2 Programs”

Dr. Cynthia Kramer

Leiden University

“Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR”

Dr. Zuben Sauna


Understanding and navigating the immune responses to CRISPR-associated nuclease Cas9”

Dr. Amy Flaxman

University of Oxford

“Antibody responses to viral-vectored coronavirus vaccines”

Prof. Daniel Olive

IBiSA Cancer Immunomonitoring Platform

“Liquid Biopsy using K-Cytof demonstrates a role for Vg9Vd2 T cells as prognostic factor in breast cancer”

Dr. Tom Henley

Empyrean Therapeutics

“A Novel Cell Therapy for COVID-19 & Potential future Pandemics”

ProImmune Pro5® Pentamer Seminar 2021

Dr. Emilee Knowlton


“Pro5® Pentamers and ProT2® Tetramers for tracking antigen-specific T cells”

Dr. Lea Bartsch

Massachusetts General Hospital

“Identification and Characterization of Hepatitis B Virus-Specific T cells”

Dr. Natasa Strbo

University of Miami

“Induction of SARS-CoV-2 S-specific CD8+ T cells in the lungs of vaccinated mice”

ProImmune Asia: Viral Hepatitis Conference 2021

Prof. Antonio Bertoletti

Duke NUS

“Engineering T lymphocytes for chronic HBV infection immunotherapy”

Edmund Neo


“Epitope identification and clinical immune monitoring tools”

Dr. Eui-Cheol Shin


“Hepatitis Virus-specific and Bystander CD8+ T Cells in Viral Hepatitis”

Mastering Immunity Virtual 2020

Dr. Hilario Ramos

Molecular Templates

“Harnessing Endogenous Antiviral T cell Responses for Control of Cancer”

Dr. Aaron Mansfield

Mayo Clinic

“Neo-antigenic Potential of Chromosomal Rearrangements in Mesothelioma”

Dr. Emilee Knowlton


“Epitope identification and clinical immune monitoring in IO programs”

Dr. Yeojun Yun

Synteka Bio

“Syntekabio Bio's Use of Genomic Big Data in Neoantigen Prediction and Discovery”

Dr. Jeremy Fry


“An integrated approach to managing immunogenicity risk and drug immune modulation”

Dr. Lea Bartsch

Massachusetts General Hospital

“Identification and Characterization of Hepatitis B Virus-Specific T cells”

Dr. Amy Rosenberg


“Immunogenicity in the Time of COVID-19”

Dr. Tomer Hertz & Dr. Amir Aharoni

Ben Gurion University

“Protein Engineering for Reduced Immunogenicity”

Dr. Nina Le Bert

Duke NUS

“SARS-CoV-2 specific T cell Immunity in COVID 19, SARS and Uninfected Controls”

Dr. Kellie Smith

Johns Hopkins

“Tumour Reactive T cell Functional Programming in Human Cancer”

Prof. Tao Dong

University of Oxford

“Understanding SARS-CoV-2 Specific T cell Response During COVID-19 Convalescence”

Dr. Tim Hickling


“Application of Immunogenicity Prediction and Mitigation for Biotherapeutic Development”

Dr. David Withers

University of Birmingham

“Tracking Dynamic Changes in Tumour Infiltrating Lymphocytes ?? ????”

Mastering Immunity 2019

Dr. Inderpal Singh

TEVA Pharmaceuticals

“Immunogenicity risk assessment of peptide-related impurities: Current Strategies & its Challenges”

Dr. Emilee Knowlton


Epitope identification and clinical immune monitoring in immune oncology programs

Dr. Andrea Ferrante

Eli Lilly

“Assessment of MHC class II-restricted epitope prediction in silico

Dr. Katerina Alexaki


“Effects of codon optimization on biotherapeutics: Implications for immunogenicity”

Dr. Patrick Hanley

Children's National Hospital

“Antiviral T cells derived from the naïve population for patients post-transplant”

Dr. Paul Arnaboldi

New York Medical College

“Using peptide-based assays to improve the laboratory diagnosis of Lyme disease”

Dr. Rao Prabhala

Harvard Medical School

“Detailed Characterization of Immune Bio-Markers in Cancer Patients”

Dr. Vibha Jawa

Merck & Co.

“Implementation of risk assessment outputs to drive clinical immunogenicity strategy and regulatory filing-related activities”

Dr. Jeremy Fry


“An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”

Prof. Beatriz Carreno

University of Pennsylvania

“Dissecting Melanoma Neoantigen Immunity”

Dr. Karen Anderson

Arizona State University

“The Challenge of Measuring Antigenic Diversity”

Mastering Immunity Europe 2019

Dr. Stefania Capone


“Chimpanzee Adenoviral vectors: a potent & flexible platform for genetic vaccination”

Dr. Jonathan Silk


“Next Generation approaches to enhance the efficacy of SPEAR T-cells”

Dr. Marie Toussaint


“How to develop the vaccines of tomorrow”

Dr. Christos Georgiadis

Institute of Child Health, UCL

“Coupled Long Terminal-CRISPR Gene Editing for the Redirection of T cells”

Clemens Joos

Helmholtz Centre, Munich

“Gene transfer of MHC II-restricted CMV-specific TCRs for development of immunotherapy”

Dr. Tom Evans


“Heterologous prime-boost approaches to CD8+ T cell induction”

Mastering Immunity 2018

Dr. Marcus Butler

UHN Toronto

“Optimizing Adoptive T cell Therapies”

Dr. Marianne Stanford

VP Research, IMV

“De novo generation of tumor specific T cell responses utilizing a novel oncology driven delivery platform”

Dr. Emilee Knowlton


“Epitope identification and clinical immune monitoring in gene therapy and immune oncology program”

Dr. Priya Sriraman


“Measuring Host-vs-CAR-T Immune Responses”

Dr. Zuben Sauna


“Use of the MHC Associated Peptide Proteomic (MAPPs) assay to understand clinical outcomes associated with the use of Factor VIII in the treatment of Hemophilia A”

Dr. Shahla Abdollahi


“Mechanisms of Immune Modulation by the Gut Microbiome – Implications for Autoimmunity”

Dr. Amy Rosenberg


“So You Think You Have Mastered Immunity? Cautionary Tales from the Immunology Revolution”

Dr. Jeremy Fry


“An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”

Dr. Jochem Gokemeijer

Bristol-Myers Squibb

“Immunogenicity Risk Assessment Tool Box for Biologics Drug Development”

Dr. Sophie Tourdot


“Non-clinical immunogenicity risk assessment of therapeutic proteins”

Dr. Andrea Ferrante


“In silico prediction of immunogenicity: filling the gaps”

Dr. Rodd Polsky


“Format and Interpretation of a Drug Tolerant Approach for Measuring Circulating Immune Complex and Free Anti-Drug Antibodies in Preclinical Studies”

Mastering Immunity Europe 2018

Dr. Lotta Jansson


“Apitopes to induce immune tolerance - mechanism and action”

Dr. Aileen Rowan

Imperial College, London

“Turnover and transformation of T cell clones in retroviral infection and leukaemia”

Prof. Paul Brenchley

University of Manchester

“Identifying T & B Cell autoantigen epitopes in Autoimmune Membranous Nephropathy”

Dr. Margot El-Khouri


“Epitope identification and clinical immune monitoring in immune oncology programs”

Dr. Yongliang Zhang

National University Singapore

“DUSP10 in inflammation and cancer”

Dr. Guy Hermans


“Using synthetic antibody libraries to overcome poor immunogenicity”

Dr. Katie Ewer

University of Oxford

“Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children”

Dr. Ilaria Esposito

University of Oxford

“Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV”

Dr. Isabelle Turbica

Université Paris-Sud

“Impact of protein aggregates from biopharmaceuticals on dendritic cells”

Dr. Eleni Chantzoura


“Mammalian Display for TCR discovery & Phosphopeptide neoantigens as targets”

Dr. Joleen White

EMD Serono

“Low Immunogenicity of Avelumab, An Immune Checkpoint Inhibitor Demonstrating Antitumor Activity”

Dr. Richard Sainson


“Long-term in vivo anti-tumour efficacy of KY1044 (anti-ICOS) as monotherapy and in combination with anti-PD-L1”

Dr. Stephen Man

Cardiff University School of Medicine

“CD8+ T cell recognition of unusual and unnatural peptide epitopes”

Prof. Beatriz Carreno

University of Pennsylvania

“Personalized Cancer Vaccines”

Prof. Fiona Powrie

University of Oxford

“Host microbe interactions in the intestine: New therapeutic strategies in IBD”

Mastering Immunity 6 (2017)

Dr. Valerie Quarmby


“Host Cell Proteins and Immunogenicity”

Dr. Daron Forman

Bristol-Myers Squibb

“The use of immunogenicity risk assessment tools for lead optimization of biologics”

Dr. Erik Meyer


“Therapeutic Immunogenicity: Target Interference and Cut Point Evaluation”

Dr. Wojciech Jankowski


“Non-clinical Assessments of Immunogenicity”

Dr. Eric Zanelli

Déclion Holdings

“DP-C016, a phosphoTau vaccine for the treatment of tauopathies”

Dr. Nik Schwabe


“Epitope identification and clinical immune monitoring in immune oncology programmes”

Mr Govinda Sharma

British Columbia Cancer Agency

“Functional identification of CD8+ T cell epitopes by parallel interrogation of more than a million distinct peptide-coding sequences”

Dr. Scott McClain

Syngenta Crop Protection

“Bioinformatic screen and detection of immunologically relevant cross-reactive IgE-binding epitopes”

Mastering Immunity Europe 2017

Dr. Bernard Maillère

CEA, France

“Specificity and phenotype of pre-existing T cells against therapeutic proteins”

Dr. Menna Clatworthy

University of Cambridge, UK

“Immune complexes modulate immune highways and DC trafficking”

Prof. Farzin Farzaneh

King's College London, UK

“Therapeutic Cancer Vaccines”

Dr. Bartek Zuber

Swedish Orphan Biovitrum, Sweden

“Immunogenicity assessment for Affibody-Fc fusion therapeutics”

Dr. Tim Hickling

Pfizer, USA

“Applying in vitro immunogenicity assays to predicts clinical immunogenicity”

Dr. Sophie Sibéril

UPMC, Paris, France

“Analysis of peripheral T cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens”

Prof. Yu-Chan Chao

Academia Sinica, Taiwan

“Display of foreign surface antigens on baculovirus as pseudotyped viruses for immunological studies and applications”

Prof. Tim Elliott

University of Southampton, UK

“Applying mechanism based computational models to CTL epitope prediction”

Prof. Mark Exley

Agenus Inc., USA

“Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options”

Prof. Christine Falk

Medizinische Hochschule Hannover, Germany

“Precision Medicine in Transplantation - immune monitoring for the discrimination of GVHD, rejection and CMV infection”

Prof. Miles Carroll

Public Health England, UK

“Understanding the immune response to EBOV during acute disease and in EVD survivors”

Mastering Immunity Europe 2016

Prof. Herman Waldmann

University of Oxford

“Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms”

Dr. Farnaz Fallah-Arani

UCB Pharma, UK

“Challenges to experimental design to test immunotherapeutic drugs to achieve clinically relevant results.”

Dr. Bernd Schlereth

Covagen, Switzerland

“Special considerations in pharmacokinetic and immunogenicity assessment of bispecific antibody constructs”

Dr. Bernard Maillère

CEA, France

“Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”

Prof. David Wraith

University of Bristol

“Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”

Dr. Peter Adler Wurtzen

ALK-Abelló, Denmark

“Immunological biomarkers in Allergy Immunotherapy”

Prof. Paul Moss

University of Birmingham

“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”

Prof. Ada Kruisbeek

DCPrime, The Netherlands

“Developing off-the-shelf dendritic cell based vaccines: pre-clinical and clinical observations”

Dr. Wei Xue

Roche Innovation Center Zurich, Switzerland

“Combination immunotherapy and vaccines in cancer”

Mastering Immunity 5 (2015)

Dr. Ethan Shevach


“Tregs -ready for the clinic”

Dr. Keith Knutson

Mayo Clinic, Jacksonville

“Vaccines for Prevention of Breast Cancer”

Prof. Jean Rommelaere

DKFZ, Germany

“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”

Dr. Xiaoying Chen

Pfizer, Inc.

“A Systems Pharmacology Approach to Immunogenicity – A multi-scale, Mechanistic Mathematical Model and Its Applications”

Prof. Armagan Kocer

University of Groningen

“Ion channel decorated liposomes: therapeutic potential and immunogenicity”

Prof. David Wraith

University of Bristol

“Switching off immunity: the mechanism of antigen-specific immunotherapy”

Prof. Julio Delgado

University of Utah

“Assessment of TNF-alpha antagonists and Anti-Drug Antibodies in the Clinical Laboratory”

Dr. Gene Olinger


“Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans”

Prof. Lawrence Steinman

Stanford University

“Vaccines, adjuvants, and autoimmunity”

Mastering Immunogenicity 4 (2014)

Prof. Herman Waldmann

University of Oxford

“Tolerance can be induced in the adult immune system”

Prof. Arlene Sharpe

Harvard University

“T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”

Dr. Timothy Hickling

Pfizer, Inc.

“Contribution of ex vivo assays to immunogenicity risk assessment”

Dr. Sabine Zollner

CSL Behring

“Preclinical characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII under clinical development at CSL Behring”

Dr. Nades Palaniya

The Hospital for Sick Children, Toronto

“Targeting innate immune collectins and neutrophil extracellular traps (NETs) to regulate inflammatory diseases”

Dr. Joleen White

Biogen IDEC

“Evaluation of Peginterferon Beta-1a and Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Immunogenicity in Multiple Sclerosis”

Dr. Bruce Hall

University of New South Wales

“Antigen specific CD4+CD25+Foxp3+Treg generated from natural Treg (nTreg)”

Dr. Amy Loercher


“ABIRISK Developments and Challenges: Perspectives from Year 2”

Dr. Susan Kirshner


“Therapeutic Proteins: Routes of Exposure and the risk of immunogenicity”

Mastering Immunogenicity 3 (2013)

Prof. David Wraith

University of Bristol

“Dealing with Unwanted Immunogenicity: The Design and Development of Tolerogenic T Cell Epitopes”

Dr. Florian Deisenhammer


“Drug Immunogenicity: Lessons Learnt from Interferon-beta”

Dr. Beth Chang


“XTEN in Blood Factor Engineering”

Dr. William Sanderson

University College London

“Phenotypic Structure of B Cell Subsets as a Tool for the Investigation for Immunogenicity”

Dr. Michael Cancro

University of Pennsylvania

“B Cell Selection and Survival: First Order Consideration for Immunogenicity”

Dr. Larry Kauver


“Antibody Repertoire Monitoring: Application to Anti-Drug Antibodies”

Dr. Samuel Pine


“Immunologic Endpoints for Guiding Biologic Drug Development”

Dr. Caroline Barelle

University of Aberdeen

“Shark VNAR Domains: Immunogenicity Determination in the Early Stages of Development Aids Candidate Selection for "First-Man" Studies”

Dr. Federico Mingozzi

University Pierre et Marie Curie

“Assessing and Modulating Immune Responses to AVV Vectors in Humans”

Mastering Immunogenicity 2 (2012)

Dr. Manoj Rajadhyaksha


“Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management”

Dr. Bonnie Rup


“Understanding the problem of unwanted immunogenicity risk in biotherapeutic discovery and development: advances, gaps, opportunities”

Dr. Nikolai Schwabe


“Mastering Immunity: ProStorm™ Cytokine Release Assay”

Dr. Bob DuBridge

Full Spectrum Genetics

“MapEng™ A Powerful, New Tool in the Engineering of Biobetter Therapeutics”

Best Practice Immunogenicity Risk Management (2012)

Dr. Tim Hickling


“Immunogenicity of biotherapeutics: Why do we care and where do we stand?”

Dr. Robin Thorpe

NIBSC Health Protection Agency

“CHMP Guidance on Unwanted Immunogencity: Best Practice Iummunogenicity Risk Management: Oxford 2012”

Dr. Katharina Steinitz

Baxter Innovations GmbH

“Identification of promiscuous FVIII-specific CD4+ T-cell epitopes in a humanized mouse model for hemophilia A”

Dr. Heather Hinton


“Pre-Clinical Risk Assesment Using Innovative Technologies”

Dr. David Ulaeto


“Therapeutic potential of a humanised antibody for the treatment of Venezuelan Equine Encephalitis Virus”